Business ❯ Biotechnology ❯ Pharmaceuticals
Clinical Trials Antibody-Drug Conjugates Obesity Treatments AI in Drug Discovery Autoimmune Diseases Clinical Research Licensing Agreements Oncology Summit Therapeutics mRNA Technology Psilocybin Treatments Efficacy and Safety Results Protein Therapeutics Immunology Oral Therapies Contract Manufacturing Research Collaboration Alzheimer's Treatment Celltrion Vepdegestrant Regulatory Approval Bispecific Antibodies Acquisitions Drug-Fc Conjugates Eli Lilly and Company Multiple Sclerosis Generative AI Regulatory Affairs New Drug Application Genetically Modified Organisms Partnership Strategies Rare Diseases AI in Pharmaceuticals FDA Approvals Allergy Therapeutics Cystic Fibrosis Anti-IgE Therapy Cardiovascular Therapeutics CAR-T Therapy siRNA Therapies T Cell Engagers Acquisition Antibody Therapeutics Antibodies Functional Cell Lines FDA Leadership Cell Therapy TN-201 Gene Therapy Kidney Diseases Clinical Efficacy Muscular Dystrophy Genmab Cystic Fibrosis Treatment
Want to see what podcasts are saying about this topic? Search across 140K+ podcasts. Explore Radar
The purchase brings an oral once‑daily acromegaly pill and a late‑stage ACTH candidate to Vertex, signaling a strategic push beyond its cystic fibrosis business.
